StockMacro
Company, fund or insider

Help

Menu

AtriCure

$55.39 +92% in 6 monthsMarket cap $2.8B

ATRC on XNAS, Health Care, AtriCure, Inc., job postings

Measures activity, not value. Not investment advice.

Stock up 96% in six months as revenue rose 14% to $589.8M over the last year.

  • GoodNew institutional positions 75, 2.7 times a year earlier
  • WatchCapital spending $6.4M last quarter, up 145%

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
1,350
Website
atricure.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $154.4M, net income $4.1M.
Quarter to 31 Dec 2021: revenue $73.2M, net income -$13.7MQuarter to 31 Dec 2021: revenue $73.2M, net income -$13.7MQuarter to 31 Mar 2022: revenue $74.6M, net income -$15.2MQuarter to 31 Mar 2022: revenue $74.6M, net income -$15.2MQuarter to 30 Jun 2022: revenue $84.5M, net income -$14.8MQuarter to 30 Jun 2022: revenue $84.5M, net income -$14.8MQuarter to 30 Sep 2022: revenue $83.2M, net income -$12.3MQuarter to 30 Sep 2022: revenue $83.2M, net income -$12.3MQuarter to 31 Dec 2022: revenue $88.0M, net income -$4.2MQuarter to 31 Dec 2022: revenue $88.0M, net income -$4.2MQuarter to 31 Mar 2023: revenue $93.5M, net income -$6.5MQuarter to 31 Mar 2023: revenue $93.5M, net income -$6.5MQuarter to 30 Jun 2023: revenue $100.9M, net income -$5.1MQuarter to 30 Jun 2023: revenue $100.9M, net income -$5.1MQuarter to 30 Sep 2023: revenue $98.3M, net income -$9.1MQuarter to 30 Sep 2023: revenue $98.3M, net income -$9.1MQuarter to 31 Dec 2023: revenue $106.5M, net income -$9.8MQuarter to 31 Dec 2023: revenue $106.5M, net income -$9.8MQuarter to 31 Mar 2024: revenue $108.9M, net income -$13.3MQuarter to 31 Mar 2024: revenue $108.9M, net income -$13.3MQuarter to 30 Jun 2024: revenue $116.3M, net income -$8.0MQuarter to 30 Jun 2024: revenue $116.3M, net income -$8.0MQuarter to 30 Sep 2024: revenue $115.9M, net income -$7.9MQuarter to 30 Sep 2024: revenue $115.9M, net income -$7.9MQuarter to 31 Dec 2024: revenue $124.3M, net income -$15.6MQuarter to 31 Dec 2024: revenue $124.3M, net income -$15.6MQuarter to 31 Mar 2025: revenue $123.6M, net income -$6.7MQuarter to 31 Mar 2025: revenue $123.6M, net income -$6.7MQuarter to 30 Jun 2025: revenue $136.1M, net income -$6.2MQuarter to 30 Jun 2025: revenue $136.1M, net income -$6.2MQuarter to 30 Sep 2025: revenue $134.3M, net income -$267KQuarter to 30 Sep 2025: revenue $134.3M, net income -$267KQuarter to 31 Dec 2025: revenue $140.5M, net income $1.8MQuarter to 31 Dec 2025: revenue $140.5M, net income $1.8MQuarter to 31 Mar 2026: revenue $141.2M, net income $108KQuarter to 31 Mar 2026: revenue $141.2M, net income $108KQuarter to 30 Jun 2026: revenue $153.6M, net income $9.0MQuarter to 30 Jun 2026: revenue $153.6M, net income $9.0MQuarter to 30 Sep 2026: revenue $154.4M, net income $4.1MQuarter to 30 Sep 2026: revenue $154.4M, net income $4.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $154.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$154.4M$4.1M
30 Jun 2026$153.6M$9.0M
31 Mar 2026$141.2M$108K
31 Dec 2025$140.5M$1.8M
30 Sep 2025$134.3M-$267K
30 Jun 2025$136.1M-$6.2M
31 Mar 2025$123.6M-$6.7M
31 Dec 2024$124.3M-$15.6M
30 Sep 2024$115.9M-$7.9M
30 Jun 2024$116.3M-$8.0M
31 Mar 2024$108.9M-$13.3M
31 Dec 2023$106.5M-$9.8M
30 Sep 2023$98.3M-$9.1M
30 Jun 2023$100.9M-$5.1M
31 Mar 2023$93.5M-$6.5M
31 Dec 2022$88.0M-$4.2M
30 Sep 2022$83.2M-$12.3M
30 Jun 2022$84.5M-$14.8M
31 Mar 2022$74.6M-$15.2M
31 Dec 2021$73.2M-$13.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $589.8M $518.3M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +14% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $14.9M -$28.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $0.30 -$0.61
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 76.7% 74.9% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 2.9% -5.1% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 2.5% -5.6% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 2.9% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $52.9M $33.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $187.0M $147.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $61.0M $61.9M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$126.0M (net cash) -$86.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.11 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $10.47
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 190 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 4.8 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 4.6 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.3 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
AtriCureATRC (this company) $2.8B1904.8+14%2.5%
iRhythmIRTC $3.2Bloss3.7+22%-4.5%
Pulse BiosciencesPLSE $3.4Blossover 999+1637%–
UFP TechnologiesUFPT $2.3B29.43.5+8.6%11.8%
HeartflowHTFL $4.1Bloss17.2+47%-33.1%
ICU MedicalICUI $4.3B71.52.0-5.9%2.8%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+15%

$154.4M vs $134.3M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+145%

$6.4M vs $2.6M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$2.3M

bought $0, sold $2.3M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+14%

283 13F filers vs 249

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

53.6M shares held by 13F filers (30 Sep 2026) of 50.9M outstanding (2 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

9.6%

4.9M shares sold short (30 Oct 2026) of 50.9M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.6

4.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+0.1%

4.9M shares sold short in the report before, 4.9M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

68%

68% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

60

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-27%

8 vs 11 applications

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$213K

the 12 months before: -$46K

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$70K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

11 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 75, 2.7× a year earlier
  • Capital spending $6.4M, 2.5× a year earlier

Price $55.39 on 20 Nov 2026, +67% over 12 months (12-month range $25.86 to $65.53)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $4.4M in the last 12 months (the 12 months before: -$1.6M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 8 published in the last 12 months, -27% on the 12 months before.
Revenue per quarter. Revenue $154.4M in the latest quarter, +15% on a year earlier.
Capital spending per quarter. Capital spending $6.4M in the latest quarter, +145% on a year earlier.
Institutional holders (13F filers). 283 13F filers reported holding it in the latest 13F quarter, +35% on a year earlier.
Federal obligations. Federal obligations: $204K published in the last 12 months, +283% on the 12 months before.
Lobbying spend. Lobbying spend: $70K published in the last 12 months, -16% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 75 vs usual 30.50 (2026-09-30); 2.7x the same period a year earlier
5 Nov 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 6.4M vs usual 2.7M (2026-09-30); 2.5x the same period a year earlier
6 Oct 2026Lobbying filingnew lobbying registration (POLSINELLI PC)
2 Jun 2026Sharp changeShort interest spike: short interest spike, 4.4M vs usual 2.3M (2026-05-15); 2.8x the same period a year earlier
19 May 20268-K and other filingsDirector or officer change
19 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 May 2026Sharp changeShort interest spike: short interest spike, 3.9M vs usual 2.3M (2026-04-30); 2.5x the same period a year earlier
20 May 20258-K and other filingsDirector or officer change
20 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Oct 2024Lobbying filinglobbying engagement terminated (FOLEY HOAG LLP)
14 May 20248-K and other filingsDirector or officer change
14 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Jan 20248-K and other filingsA major agreement ended
4 Jan 20248-K and other filingsDirector or officer change
4 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Jul 2023Lobbying filinglobbying engagement terminated (HANCE SCARBOROUGH)
26 May 20238-K and other filingsDirector or officer change
26 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Mar 2023Lobbying filingnew lobbying registration (FOLEY HOAG LLP)
19 Jul 2022Lobbying filingnew lobbying registration (HANCE SCARBOROUGH)
27 May 20228-K and other filingsDirector or officer change
27 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$108K published
Month from 1 Jan 2022: -$180K published
Month from 1 Feb 2022: -$169K published
Month from 1 Mar 2022: -$437K published
Month from 1 Apr 2022: -$17K published
Month from 1 May 2022: -$137K published
Month from 1 Sep 2022: -$229K published
Month from 1 May 2023: -$401K published
Month from 1 Jun 2023: -$101K published
Month from 1 Jul 2023: -$195K published
Month from 1 Nov 2023: -$43K published
Month from 1 Mar 2024: -$423K published
Month from 1 Apr 2024: -$46K published
Month from 1 May 2024: -$36K published
Month from 1 Jun 2024: $111K published
Month from 1 Aug 2024: -$84K published
Month from 1 Mar 2025: -$233K published
Month from 1 May 2025: -$84K published
Month from 1 Aug 2025: -$547K published
Month from 1 Sep 2025: -$109K published
Month from 1 Nov 2025: -$676K published
Month from 1 Mar 2026: -$149K published
Month from 1 May 2026: -$227K published
Month from 1 Jul 2026: -$1.4M published
Month from 1 Aug 2026: -$731K published
Month from 1 Sep 2026: -$1.2M published
Month from 1 Nov 2026: -$690K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 2 published
Quarter from 1 Apr 2022: 2 published
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Oct 2022: 4 published
Quarter from 1 Jan 2023: 2 published
Quarter from 1 Jul 2023: 2 published
Quarter from 1 Oct 2023: 3 published
Quarter from 1 Jan 2024: 2 published
Quarter from 1 Apr 2024: 3 published
Quarter from 1 Jul 2024: 3 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Apr 2025: 2 published
Quarter from 1 Jul 2025: 5 published
Quarter from 1 Oct 2025: 3 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 2 published
Quarter from 1 Jul 2026: 4 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $73.2M, +27% on a year earlier; public on 5 May 2022
Quarter ended 31 Mar 2022: $74.6M, +26% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $84.5M, +18% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $83.2M, +18% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $88.0M, +20% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $93.5M, +25% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $100.9M, +19% on a year earlier; public on 27 Jul 2023
Quarter ended 30 Sep 2023: $98.3M, +18% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $106.5M, +21% on a year earlier; public on 17 Feb 2024
Quarter ended 31 Mar 2024: $108.9M, +16% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $116.3M, +15% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $115.9M, +18% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $124.3M, +17% on a year earlier; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $123.6M, +14% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $136.1M, +17% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $134.3M, +16% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $140.5M, +13% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $141.2M, +14% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $153.6M, +13% on a year earlier; public on 28 Jul 2026
Quarter ended 30 Sep 2026: $154.4M, +15% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $2.7M, +158% on a year earlier; public on 18 Feb 2022
Quarter ended 31 Mar 2022: $3.4M, +155% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $4.2M, -0.7% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $5.1M, +242% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $4.2M, +54% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $2.5M, -26% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $3.1M, -26% on a year earlier; public on 27 Jul 2023
Quarter ended 30 Sep 2023: $3.6M, -29% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $2.8M, -33% on a year earlier; public on 17 Feb 2024
Quarter ended 31 Mar 2024: $2.8M, +11% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $2.4M, -23% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $3.6M, -0.6% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $2.7M, -3.3% on a year earlier; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $2.2M, -21% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $2.7M, +12% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $2.6M, -28% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $1.6M, -41% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $3.9M, +77% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $3.8M, +41% on a year earlier; public on 28 Jul 2026
Quarter ended 30 Sep 2026: $6.4M, +145% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 202; public on 14 Feb 2022
31 Mar 2022 report: 206; public on 16 May 2022
30 Jun 2022 report: 201; public on 15 Aug 2022
30 Sep 2022 report: 196; public on 14 Nov 2022
31 Dec 2022 report: 198; public on 14 Feb 2023
31 Mar 2023 report: 212; public on 15 May 2023
30 Jun 2023 report: 211; public on 14 Aug 2023
30 Sep 2023 report: 211; public on 14 Nov 2023
31 Dec 2023 report: 219; public on 14 Feb 2024
31 Mar 2024 report: 213; public on 15 May 2024
30 Jun 2024 report: 188; public on 14 Aug 2024
30 Sep 2024 report: 191; public on 14 Nov 2024
31 Dec 2024 report: 210; public on 14 Feb 2025
31 Mar 2025 report: 212; public on 15 May 2025
30 Jun 2025 report: 194; public on 14 Aug 2025
30 Sep 2025 report: 210; public on 14 Nov 2025
31 Dec 2025 report: 229; public on 17 Feb 2026
31 Mar 2026 report: 218; public on 15 May 2026
30 Jun 2026 report: 249; public on 14 Aug 2026
30 Sep 2026 report: 283; public on 16 Nov 2026
Federal obligations
Month from 1 Jan 2022: $15K published
Month from 1 Apr 2022: $91K published
Month from 1 Jun 2022: $26K published
Month from 1 Oct 2022: $12K published
Month from 1 Jan 2023: $91K published
Month from 1 Apr 2023: $112K published
Month from 1 May 2023: $0 published
Month from 1 Jun 2023: $11K published
Month from 1 Aug 2023: $19K published
Month from 1 Jan 2024: $11K published
Month from 1 Mar 2024: $10K published
Month from 1 May 2024: -$75K published
Month from 1 Aug 2024: -$91K published
Month from 1 Mar 2025: $10K published
Month from 1 Jun 2025: $11K published
Month from 1 Jul 2025: $24K published
Month from 1 Sep 2025: $19K published
Month from 1 Oct 2025: -$10K published
Month from 1 Feb 2026: $48K published
Month from 1 Mar 2026: $100K published
Month from 1 May 2026: $66K published
Month from 1 Jun 2026: -$10K published
Lobbying spend
Quarter from 1 Jul 2022: $10K published
Quarter from 1 Oct 2022: $10K published
Quarter from 1 Jan 2023: $20K published
Quarter from 1 Apr 2023: $15K published
Quarter from 1 Jul 2023: $20K published
Quarter from 1 Oct 2023: $18K published
Quarter from 1 Apr 2024: $22K published
Quarter from 1 Jul 2024: $22K published
Quarter from 1 Oct 2024: $22K published
Quarter from 1 Jan 2025: $22K published
Quarter from 1 Apr 2025: $18K published
Quarter from 1 Jul 2025: $22K published
Quarter from 1 Oct 2025: $20K published
Quarter from 1 Jan 2026: $20K published
Quarter from 1 Apr 2026: $20K published
Quarter from 1 Jul 2026: $20K published
Quarter from 1 Oct 2026: $10K published

What is unusual now

  • Made public in the last 90 days: it saw 75 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year; it also spent $6.4M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year. Two or more unrelated kinds of activity agreed on 17 Nov 2026.
  • Many funds opening a new position: saw 75 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year Public on 16 Nov 2026.
  • Short interest spike: had 4.4M shares sold short in the 15 May 2026 report, 2.8× the same report last year Public on 28 May 2026.
  • Quarterly capital spending jump: spent $6.4M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year Public on 5 Nov 2026.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 7 sales, $2.3M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
10 Nov 2026B Kristine JohnsonDirectorSell2,452$58.48$143KForm 4
5 Nov 2026Salvatore PriviteraChief Technical OfficerSellplanned in advance (10b5-1)8,404$65.00$546KForm 4
24 Sep 2026Salvatore PriviteraChief Technical OfficerSellplanned in advance (10b5-1)4,519$60.00$271KForm 4
14 Sep 2026Regina E GrovesDirectorSell5,313$54.22$288KForm 4
10 Sep 2026Salvatore PriviteraChief Technical OfficerSellplanned in advance (10b5-1)3,657$55.00$201KForm 4
4 Sep 2026Salvatore PriviteraChief Technical OfficerSellplanned in advance (10b5-1)7,763$52.50$408KForm 4
26 Aug 2026Karl S. DahlquistChief Legal OfficerSell9,370$48.89$458KForm 4
7 Aug 2026Karen PrangeDirectorSell3,564$38.80$138KForm 4

283 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 73 opened a position, 42 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.7.9M15.6%$446.4M+3.5M+78%
Wellington Management Group LLP4.1M8.08%$231.3M+621K+18%
Vanguard Portfolio Management LLC3.6M7.12%$203.8M+500K+16%
Alliancebernstein L.P.2.9M5.75%$164.5M+158K+5.7%
Hood River Capital Management LLC2.8M5.58%$159.8M-63K-2.2%
Vanguard Capital Management LLC2.2M4.31%$123.3M+3,214+0.1%
State Street Corp2.1M4.18%$119.6M+739K+53%
Nomura Asset Management International Inc.1.5M2.92%$83.5M-248K-14%
Geode Capital Management, LLC1.3M2.56%$73.2M-17K-1.3%
Goldman Sachs Group Inc1.1M2.18%$62.3M-489K-31%

Company events

All 31 company events

In 12 months: 1 major agreement, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
19 May 2026Director or officer changeSame filing: shareholder vote results8-K
12 Jan 2026Signed a major agreementSame filing: took on new debt8-K
20 May 2025Director or officer changeSame filing: shareholder vote results8-K
14 May 2024Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
8 Jan 2024Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
4 Jan 2024Director or officer change8-K
26 May 2023Director or officer changeSame filing: shareholder vote results8-K
27 May 2022Director or officer changeSame filing: shareholder vote results8-K

60 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 48%, Finance & accounting 8%, Manufacturing & production 8%, Marketing & communications 7%.

PostedJobLocation
20 Nov 2026Sourcing Project Engineer Co-op (Summer 2027)Supply chain & procurementMason, OH
20 Nov 2026Cryo Nerve Block Clinical Specialist-TucsonSales & business developmentTucson, AZ
19 Nov 2026Accounts Payable SpecialistFinance & accountingMason, OH
19 Nov 2026Marketing Manager, ANZMarketing & communicationsMelbourne, Australia; Sydney, Australia
18 Nov 2026Cryo Nerve Block Clinical Specialist-RichmondSales & business developmentRichmond, VA
18 Nov 2026Office & Facilities ManagerFacilities & constructionAmsterdam, Netherlands
16 Nov 2026Clinical SpecialistSales & business developmentBirmingham, United Kingdom
16 Nov 2026Training and Education Manager - JapanSupply chain & procurementNagoya, Japan; Osaka, Japan; Tokyo, Japan

Reported lobbying spend: $10K in Q3 2026, $20K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Sep 2026NewPolsinelli PCfor AtricureIssues related to Medicare coverage and payment for servicesMedicare/MedicaidFiling
31 Jul 2026EndedFoley Hoag LLPfor AtricureIssues related to Medicare coverage of Atrial Fibrillation and related conditions.Medicare/MedicaidFiling
21 Jun 2023EndedHance Scarboroughfor AtricureNot statedFiling
14 Feb 2023NewFoley Hoag LLPfor Atricure-Issues related to Medicare coverage of Atrial Fibrillation and related conditionsMedicare/MedicaidFiling
15 Jun 2022NewHance Scarboroughfor AtricureMedicare Reimbursement IssuesMedicare/MedicaidFiling
1 Jul 2021EndedDla Piper LLP (US)for Atricure Inc.Not statedFiling
12 Apr 2021NewDla Piper LLP (US)for Atricure Inc.Sanctions addressing IP concerns.Copyright/patentsFiling
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Nov 2026confirmed

Confirmed across sources Institutional holdings and Filings + Financials

AtriCure (ATRC): spent $6.4M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year, while it saw 75 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year. Two unrelated kinds of activity within 12 days.

  • Financials: Quarterly capital spending jump, became public on 5 Nov 2026
  • Institutional holdings: Many funds opening a new position, became public on 16 Nov 2026
2024-09-30: $3.6M2024-12-31: $2.7M2025-03-31: $2.2M2025-06-30: $2.7M2025-09-30: $2.6M2025-12-31: $1.6M2026-03-31: $3.9M2026-06-30: $3.8M2026-09-30: $6.4M
The quarter ended 30 Sep 2026 against the 8 quarters before it. this quarterearliernormal: $2.7M
See the evidence (2 changes)

Financials: Quarterly capital spending jump became public on 5 Nov 2026

AtriCure spent $6.4M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year.

This period
$6.4M (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$2.7M
Typical spread (median absolute deviation)
$714K
How far from its usual level
+3.5
Same quarter last year
$2.6M
History used
3,835 days
2024-09-30: $3.6M2024-12-31: $2.7M2025-03-31: $2.2M2025-06-30: $2.7M2025-09-30: $2.6M2025-12-31: $1.6M2026-03-31: $3.9M2026-06-30: $3.8M2026-09-30: $6.4M
the quarter ended 30 Sep 20268 earlier quartersnormal: $2.7M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

AtriCure saw 75 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year.

This period
75 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
30.5
Typical spread (median absolute deviation)
3
How far from its usual level
+10.0
Same quarter last year
28
History used
4,748 days
2024-09-30: 322024-12-31: 312025-03-31: 342025-06-30: 142025-09-30: 282025-12-31: 302026-03-31: 242026-06-30: 492026-09-30: 75
the quarter ended 30 Sep 20268 earlier quartersnormal: 30.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026several at once

    spent $6.4M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year, while it saw 75 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year. Two unrelated kinds of activity within 12 days.

    See the evidence (2 changes)

    Financials: Quarterly capital spending jump became public on 5 Nov 2026

    AtriCure spent $6.4M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year.

    This period
    $6.4M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $2.7M
    Typical spread (median absolute deviation)
    $714K
    How far from its usual level
    +3.5
    Same quarter last year
    $2.6M
    History used
    3,835 days
    2024-09-30: $3.6M2024-12-31: $2.7M2025-03-31: $2.2M2025-06-30: $2.7M2025-09-30: $2.6M2025-12-31: $1.6M2026-03-31: $3.9M2026-06-30: $3.8M2026-09-30: $6.4M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $2.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

    AtriCure saw 75 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year.

    This period
    75 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    30.5
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +10.0
    Same quarter last year
    28
    History used
    4,748 days
    2024-09-30: 322024-12-31: 312025-03-31: 342025-06-30: 142025-09-30: 282025-12-31: 302026-03-31: 242026-06-30: 492026-09-30: 75
    the quarter ended 30 Sep 20268 earlier quartersnormal: 30.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  2. 16 Nov 2026Institutional holdings change

    saw 75 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year.

    Same quarter last year: 28; its normal quarter is 30.5.

    See the evidence
    This period
    75 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    30.5
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +10.0
    Same quarter last year
    28
    History used
    4,748 days
    2024-09-30: 322024-12-31: 312025-03-31: 342025-06-30: 142025-09-30: 282025-12-31: 302026-03-31: 242026-06-30: 492026-09-30: 75
    the quarter ended 30 Sep 20268 earlier quartersnormal: 30.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  3. 5 Nov 2026Financials change

    spent $6.4M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year.

    Same quarter last year: $2.6M; its normal quarter is $2.7M.

    See the evidence
    This period
    $6.4M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $2.7M
    Typical spread (median absolute deviation)
    $714K
    How far from its usual level
    +3.5
    Same quarter last year
    $2.6M
    History used
    3,835 days
    2024-09-30: $3.6M2024-12-31: $2.7M2025-03-31: $2.2M2025-06-30: $2.7M2025-09-30: $2.6M2025-12-31: $1.6M2026-03-31: $3.9M2026-06-30: $3.8M2026-09-30: $6.4M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $2.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  4. 6 Oct 2026Lobbying record

    ATRICURE: new lobbying registration (POLSINELLI PC) (dated 1 Sep 2026)

  5. 28 May 2026Short interest and volume change

    had 4.4M shares sold short in the 15 May 2026 report, 2.8× the same report last year.

    Same report last year: 1.6M; its normal report is 2.3M.

    See the evidence
    This period
    4.4M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    2.3M
    Typical spread (median absolute deviation)
    301K
    How far from its usual level
    +4.8
    Same report last year
    1.6M
    History used
    3,059 days
    2025-05-15: 1.6M2025-05-30: 1.8M2025-06-13: 1.6M2025-06-30: 1.5M2025-07-15: 1.5M2025-07-31: 2.2M2025-08-15: 2.0M2025-08-29: 2.1M2025-09-15: 2.1M2025-09-30: 2.2M2025-10-15: 2.0M2025-10-31: 2.3M2025-11-14: 2.6M2025-11-28: 2.3M2025-12-15: 2.5M2025-12-31: 2.4M2026-01-15: 2.5M2026-01-30: 2.5M2026-02-13: 3.4M2026-02-27: 3.1M2026-03-13: 3.4M2026-03-31: 3.5M2026-04-15: 3.6M2026-04-30: 3.9M2026-05-15: 4.4M
    the 15 May 2026 report24 earlier reportsnormal: 2.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 19 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 19 May 2026Filings record

    Director or officer change

  8. 12 May 2026Short interest and volume change

    had 3.9M shares sold short in the 30 Apr 2026 report, 2.5× the same report last year.

    Same report last year: 1.5M; its normal report is 2.3M.

    See the evidence
    This period
    3.9M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    2.3M
    Typical spread (median absolute deviation)
    299K
    How far from its usual level
    +3.6
    Same report last year
    1.5M
    History used
    3,044 days
    2025-04-30: 1.5M2025-05-15: 1.6M2025-05-30: 1.8M2025-06-13: 1.6M2025-06-30: 1.5M2025-07-15: 1.5M2025-07-31: 2.2M2025-08-15: 2.0M2025-08-29: 2.1M2025-09-15: 2.1M2025-09-30: 2.2M2025-10-15: 2.0M2025-10-31: 2.3M2025-11-14: 2.6M2025-11-28: 2.3M2025-12-15: 2.5M2025-12-31: 2.4M2026-01-15: 2.5M2026-01-30: 2.5M2026-02-13: 3.4M2026-02-27: 3.1M2026-03-13: 3.4M2026-03-31: 3.5M2026-04-15: 3.6M2026-04-30: 3.9M
    the 30 Apr 2026 report24 earlier reportsnormal: 2.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 20 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 20 May 2025Filings record

    Director or officer change

  11. 20 Oct 2024Lobbying record

    ATRICURE: lobbying engagement terminated (FOLEY HOAG LLP) (dated 31 Jul 2026)

  12. 1 Jun 2024Insiders record

    Privitera Salvatore (Chief Technical Officer) bought 5,000 shares of ATRC ($111,250) (dated 31 May 2024)

  13. 14 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 14 May 2024Filings record

    Director or officer change

  15. 8 Jan 2024Filings record

    A major agreement ended

  16. 4 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 4 Jan 2024Filings record

    Director or officer change

  18. 19 Jul 2023Lobbying record

    ATRICURE: lobbying engagement terminated (HANCE SCARBOROUGH) (dated 21 Jun 2023)

  19. 26 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 26 May 2023Filings record

    Director or officer change

  21. 23 Mar 2023Lobbying record

    ATRICURE: new lobbying registration (FOLEY HOAG LLP) (dated 14 Feb 2023)

  22. 19 Jul 2022Lobbying record

    ATRICURE: new lobbying registration (HANCE SCARBOROUGH) (dated 15 Jun 2022)

  23. 27 May 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 27 May 2022Filings record

    Director or officer change

  25. 30 Oct 2021Insiders record

    GROVES REGINA E (director) bought 34 shares of ATRC ($2,607) (dated 29 Oct 2021)

  26. 20 Oct 2021Lobbying record

    ATRICURE INC.: lobbying engagement terminated (DLA PIPER LLP (US)) (dated 1 Jul 2021)

  27. 20 Jul 2021Lobbying change

    registered for federal lobbying for the first time in our data (Dla Piper Llp (Us)).

    See the evidence (1 source record)
    Source coverage starts
    6 Apr 2010
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  28. 20 Jul 2021Lobbying record

    ATRICURE INC.: new lobbying registration (DLA PIPER LLP (US)) (dated 12 Apr 2021)

  29. 15 Jun 2021Filings record

    Director or officer change

  30. 8 Apr 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 8 Apr 2021Filings record

    Director or officer change

  32. 20 Nov 2020Insiders record

    Drake Scott William (director) bought 12,350 shares of ATRC ($500,669) (dated 19 Nov 2020)

  33. 6 Aug 2020Filings record

    Director or officer change

  34. 22 May 2020Filings record

    Director or officer change

  35. 9 Apr 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 9 Apr 2020Filings record

    Director or officer change

  37. 4 Dec 2019Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 4 Dec 2019Filings record

    Director or officer change

  39. 17 Sep 2019Insiders record

    GROVES REGINA E (director) bought 500 shares of ATRC ($12,430) (dated 16 Sep 2019)

  40. 13 Aug 2019Filings record

    Completed an acquisition or asset sale

Showing the newest 40 of 52 entries; narrow the window or the kind of data to see older ones.

Not listed: 250 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001323885
Ticker
ATRC
Domain
atricure.com
Employer name
AtriCure, Inc. (1 unverified)
Hq location
OH|MASON|45040 (1 unverified)
Lobbying client
atricure
Name
AtriCure Asia Pacific PTE., Ltd., incorporated in Singapore, AtriCure (Beijing) Medicine Information Consulting Service Co., Ltd., incorporated in Beijing, AtriCure Canada, Inc., incorporated in Canada, AtriCure Europe, B.V., incorporated in the Netherlands and 10 more
Uei
GWJ6CQNT1EN6
Wikidata
Q30256881
  • DOL H-1B labor condition applications and PERM certifications239 data points2 Mar 2020 to 14 Sep 2026
  • Federal lobbying disclosures (LDA)7 records, 58 data points12 Apr 2021 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)136 records11 Jan 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1238 data points31 Dec 2008 to 2 Nov 2026
  • SEC Form 4 insider transactions143 records, 500 data points9 Mar 2016 to 10 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1299 data points11 Oct 2007 to 11 Jun 2026